Biomarkers of Leucine‐Rich Repeat Kinase 2 ( LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear Palsy

Louise‐Kristine Nielsen; Joshua L.I. Frost; David Vaughan; Raquel Real; Riona Fumi; Marte Theilmann Jensen; Megan Hodgson; Eleanor J. Stafford; Lesley Wu; Olaf Ansorge; Annelies Quaegebeur; Kieren Allinson; Thomas T. Warner; Zane Jaunmuktane; Anjum Misbahuddin; P. Nigel Leigh; B Ghosh; K P Bhatia; Alistair Church; Christopher Kobylecki; Michele T.M. Hu; James B. Rowe; Alan A Shomo; Danielle Graham; Omar S. Mabrouk; Huw R. Morris; Esther M. Sammler; Edwin Jabbari

doi:10.1002/mds.70295

Key Points

The aim is to explore biomarkers related to LRRK2 and lysosomal dysfunction in progressive supranuclear palsy (PSP).
Analyzed biochemical markers of lysosomal function in PSP patients.
Conducted genetic stratification to assess patient eligibility for LRRK2-targeting therapies.
Biochemical evidence of lysosomal dysfunction is present in PSP patients.
Genetic markers may help identify PSP patients who could benefit from specific therapies targeting LRRK2.

Implication

Identifies biomarkers for lysosomal dysfunction in PSP, suggesting potential LRRK2-targeting therapies.

Abstract

Biochemically defined lysosomal dysfunction is evident in PSP. Genetic and biochemical stratification may identify PSP patients that would benefit from LRRK2-targeting therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nielsen et al. (2026) studied this question.

synapsesocial.com/papers/69e31ff140886becb653f0ce https://doi.org/10.1002/mds.70295

View Full Paper

Ask AI

Bookmark

Share

Biomarkers of Leucine‐Rich Repeat Kinase 2 ( LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear Palsy

Key Points

Implication

Abstract

Discussion

Cite This Study

Biomarkers of Leucine‐Rich Repeat Kinase 2 ( LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear Palsy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading